Current treatment issues in female hyperprolactinaemia

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 125, Issue 2, 2006, Pages 152-164

  Crosignani, Pier Giorgio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Bromocriptine; Cabergoline; Hyperprolactinaemia; Prolactin; Quinagolide

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; BROMOCRIPTINE; BUTYROPHENONE; CABERGOLINE; CALCIUM CHANNEL BLOCKING AGENT; DOMPERIDONE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; FLUOXETINE; HALOPERIDOL; METHYLDOPA; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OPIATE; PHENOTHIAZINE; PROLACTIN; PROTEINASE INHIBITOR; QUINAGOLIDE; RESERPINE; RISPERIDONE; SULPIRIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

ABDOMINAL PAIN; ABORTION; AMENORRHEA; CHROMATOGRAPHY; CONGENITAL MALFORMATION; DIZZINESS; DOPAMINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FEMALE INFERTILITY; GALACTORRHEA; GONADAL DISEASE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOPHYSIS TUMOR; HYPOTHALAMUS; HYPOTHALAMUS DISEASE; IMMUNOASSAY; IMMUNOPRECIPITATION; LACTATION; MEMORY DISORDER; MULTIPLE DRUG DOSE; MULTIPLE PREGNANCY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOMENORRHEA; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PATIENT COMPLIANCE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN SYNTHESIS; PROLACTINOMA; REVIEW; SURGICAL TECHNIQUE; SYNCOPE; TUMOR VOLUME;

EID: 33645885331     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2005.10.005     Document Type: Review

References (99)

1. Freeman M.E., Kanyicska B., Lerant A., and Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 80 (2000) 1523-1631
2. Mah P.M., and Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Seminars Reprod Med 20 (2002) 365-374
3. Asa S.L., and Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer 2 (2002) 836-849
4. Marken P.A., Haykal R.F., and Fisher J.N. Management of psychotropic-induced hyperprolactinemia. Clin Pharmacol 11 (1992) 851-856
5. Serri O., Chik C.L., Ur E., and Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ 169 (2003) 575-581
6. Verhelst J., and Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2 (2003) 23-32
7. Schlechte J., Dolan K., Sherman B., Chapler F., and Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68 (1989) 412-418
8. Leite V., Cosby H., Sobrinho L.G., Fresnoza M.A., Santos M.A., and Friesen H.G. Characterization of big, big prolactin in patients with hyperprolactinaemia. Clin Endocrinol (Oxford) 37 (1992) 365-372
9. Yuen Y.P., Lai J.P., Au K.M., Chan A.Y., and Mak T.W. Macroprolactin-a cause of pseudohyperprolactinaemia. Hong Kong Med J 9 (2003) 119-121
10. Bonhoff A., Vuille J.C., Gomez F., and Gellersen B. Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL-IgG complex. Exp Clin Endocrinol Diabetes 103 (1995) 252-255
11. Vallette-Kasic S., Morange-Ramos I., Selim A., et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 87 (2002) 581-588
12. Strachan M.W., Teoh W.L., Don-Wauchope A.C., Seth J., Stoddart M., and Beckett G.J. Clinical and radiological features of patients with macroprolactinaemia. Clin Endocrinol (Oxford) 59 (2003) 339-346
13. Cavaco B., Prazeres S., Santos M.A., Sobrinho L.G., and Leite V. Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays. J Endocrinol Invest 22 (1999) 203-208
14. Gibney J., Smith T.P., and McKenna T.J. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 90 (2005) 3927-3932
15. Milewicz A. Prolactin levels in the polycystic ovary syndrome. J Reprod Med 29 (1984) 193-196
16. Grattan D.R. Behavioural significance of prolactin signalling in the central nervous system during pregnancy and lactation. Reproduction 123 (2002) 497-506
17. Crosignani P.G., Meschia M., Bruschi F., and Parazzini F. Sustained prolactin release associated with precocious ovarian failure. Gynecol Obstet Invest 39 (1995) 63-64
18. Luciano A.A. Clinical presentation of hyperprolactinemia. J Reprod Med 44 (1999) 1085-1090
19. Biller B.M., Luciano A., Crosignani P.G., et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 44 (1999) 1075-1084
20. Greer M.E., Moraczewski T., and Rakoff J.S. Prevalence of hyperprolactinemia in anovulatory women. Obstet Gynecol 56 (1980) 65-69
21. Miller K.K., and Klibanski A. Clinical review 106: amenorrheic bone loss. J Clin Endocrinol Metab 84 (1999) 1775-1783
22. Greenspan S.L., Oppenheim D.S., and Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110 (1989) 526-531
23. Schlechte J., Sherman B., and Martin R. Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 56 (1983) 1120-1123
24. Wieck A., and Haddad P. Hyperprolactinaemia caused by antipsychotic drugs. BMJ 324 (2002) 250-252
25. Koppelman M.C., Kurtz D.W., Morrish K.A., et al. Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab 59 (1984) 1050-1053
26. Schlechte J., el-Khoury G., Kathol M., and Walkner L. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64 (1987) 1021-1026
27. Vartej P., Poiana C., and Vartej I. Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women. Gynecol Endocrinol 15 (2001) 43-47
28. Yermus R., and Ezzat S. Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas?. Clin Endocrinol (Oxford) 56 (2002) 562
29. Greenman Y., Tordjman K., and Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxford) 48 (1998) 547-553
30. Vercellini P., Sacerdote P., Trespidi L., Manfredi B., Panerai A.E., and Crosignani P.G. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study. Fertil Steril 62 (1994) 938-942
31. Di Somma C., Colao A., Di Sarno A., et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 83 (1998) 807-813
32. Rand T., Kink E., Sator M., et al. MRI of microadenomas in patients with hyperprolactinaemia. Neuroradiology 38 (1996) 744-746
33. Bayrak A., Saadat P., Mor E., Chong L., Paulson R.J., and Sokol R.Z. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril 84 (2005) 181-185
34. Smith T.P., Suliman A.M., Fahie-Wilson M.N., and McKenna T.J. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 87 (2002) 5410-5415
35. Olukoga A.O., and Kane J.W. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxford) 51 (1999) 119-126
36. Testa G., Vegetti W., Motta T., et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58 (1998) 69-73
37. Franks S., Horrocks P.M., Lynch S.S., Butt W.R., and London D.R. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia. Brit Med J (Clin Res Ed) 286 (1983) 1177-1179
38. Levey A.I., Hersch S.M., Rye D.B., et al. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA 90 (1993) 8861-8865
39. Ben-Jonathan N., and Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22 (2001) 724-763
40. Schoors D.F., Vauquelin G.P., De Vos H., et al. Identification of a D1 dopamine receptor, not linked to adenylate cyclase, on lactotroph cells. Brit J Pharmacol 103 (1991) 1928-1934
41. Jose P.A., Eisner G.M., and Felder R.A. Renal dopamine receptors in health and hypertension. Pharmacol Ther 80 (1998) 149-182
42. Mannelli M., Lazzeri C., Ianni L., et al. Dopamine and sympathoadrenal activity in man. Clin Exp Hypertens 19 (1997) 163-179
43. Bankowski B.J., and Zacur H.A. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol 46 (2003) 349-362
44. Vance M.L., Evans W.S., and Thorner M.O. Drugs 5 years later. Bromocriptine. Ann Intern Med 100 (1984) 78-91
45. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., and Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331 (1994) 904-909
46. Touraine P., Plu-Bureau G., Beji C., Mauvais-Jarvis P., and Kuttenn F. Long-term follow-up of 246 hyperprolactinemic patients. Acta Obstet Gynecol Scand 80 (2001) 162-168
47. Moriondo P., Travaglini P., Nissim M., Conti A., and Faglia G. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60 (1985) 764-772
48. Essais O., Bouguerra R., Hamzaoui J., et al. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. Ann Endocrinol (Paris) 63 (2002) 524-531
49. Di Sarno A., Landi M.L., Cappabianca P., et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86 (2001) 5256-5261
50. Hawkins T. Impact of once- and twice-daily dosing regimens on adherence and overall safety. AIDS Reader 14 (2004) 320-322 324, 329-31, 334-6
51. Moyle G. Once-daily therapy: less is more. Int J STD AIDS 14 Suppl 1 (2003) 1-5
52. Greenberg R.N. Overview of patient compliance with medication dosing: a literature review. Clin Ther 6 (1984) 592-599
53. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 (2001) 1296-1310
54. Ferrari C., Barbieri C., Caldara R., et al. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 63 (1986) 941-945
55. Biller B.M., Molitch M.E., Vance M.L., et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81 (1996) 2338-2343
56. Colao A., Di Sarno A., Landi M.L., et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85 (2000) 2247-2252
57. Ciccarelli E., Giusti M., Miola C., et al. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 69 (1989) 725-728
58. Verhelst J., Abs R., Maiter D., et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84 (1999) 2518-2522
59. Ferrari C.I., Abs R., Bevan J.S., et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxford) 46 (1997) 409-413
60. Ciccarelli E., Grottoli S., Razzore P., et al. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest 20 (1997) 547-551
61. Brooks D.J. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 68 (2000) 685-689
62. van der Heijden P.F., Rolland R., Thomas C.M., and Brownell J. Endocrine effects of CV 205-502, a new dopamine agonist, in hyperprolactinemic women. Gynecol Endocrinol 2 (1988) 233-248
63. van der Heijden P.F., Lappohn R.E., Corbey R.S., de Goeij W.B., Brownell J., and Rolland R. The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study. Fertil Steril 52 (1989) 574-579
64. Homburg R., West C., Brownell J., and Jacobs H.S. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol (Oxford) 32 (1990) 565-571
65. Glaser B., Nesher Y., and Barziliai S. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502. J Reprod Med 39 (1994) 449-454
66. van der Heijden P.F., de Wit W., Brownell J., Schoemaker J., and Rolland R. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 40 (1991) 111-118
67. van der Lely A.J., Brownell J., and Lamberts S.W. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 72 (1991) 1136-1141
68. Schultz P.N., Ginsberg L., McCutcheon I.E., Samaan N., Leavens M., and Gagel R.F. Quinagolide in the management of prolactinoma. Pituitary 3 (2000) 239-249
69. Rohmer V., Freneau E., Morange I., and Simonetta C. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse. Ann Endocrinol (Paris) 61 (2000) 411-417
70. Morange I., Barlier A., Pellegrini I., Brue T., Enjalbert A., and Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 135 (1996) 413-420
71. Duranteau L., Chanson P., Lavoinne A., Horlait S., Lubetzki J., and Kuhn J.M. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clin Endocrinol (Oxford) 34 (1991) 25-29
72. Di Sarno A., Landi M.L., Marzullo P., et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxford) 53 (2000) 53-60
73. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Safety 14 (1996) 228-238
74. Vilar L., and Burke C.W. Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine. Clin Endocrinol (Oxford) 41 (1994) 821-826
75. Merola B., Sarnacchiaro F., Colao A., et al. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 8 (1994) 175-181
76. De Luis D.A., Becerra A., Lahera M., Botella J.I., Valero, and Varela C. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J Endocrinol Invest 23 (2000) 428-434
77. Colao A., Loche S., Cappa M., et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 83 (1998) 2777-2780
78. Giusti M., Porcella E., Carraro A., Cuttica M., Valenti S., and Giordano G. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. J Endocrinol Invest 17 (1994) 51-57
79. Parlodel tablets (bromocriptine). United Kingdom summary of product characteristics, 2004.
80. Weil C. The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 10 (1986) 172-195
81. Robert E., Musatti L., Piscitelli G., and Ferrari C.I. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10 (1996) 333-337
82. In: Molitch M. (Ed). Manifestations, epidemiology and pathogenesis of prolactinomas in women. In: Olefsky J., and Robbins R. (Eds). Prolactinomas (1986), Churchill Livingstone, New York 67-95
83. Crosignani P., Ferrari C., and Mattei A.M. Visual field defects and reduced visual acuity during pregnancy in two patients with prolactinoma: rapid regression of symptoms under bromocriptine. Case reports. Brit J Obstet Gynaecol 91 (1984) 821-823
84. Tan S.L., and Jacobs H.S. Rapid regression through bromocriptine therapy of a suprasellar extending prolactinoma during pregnancy. Int J Gynaecol Obstet 24 (1986) 209-215
85. Crosignani P.G., Mattei A.M., Scarduelli C., Cavioni V., and Boracchi P. Is pregnancy the best treatment for hyperprolactinaemia?. Hum Reprod 4 (1989) 910-912
86. Delgrange E., Maiter D., and Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 134 (1996) 454-456
87. Passos V.Q., Souza J.J., Musolino N.R., and Bronstein M.D. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87 (2002) 3578-3582
88. Kovacs K., Stefaneanu L., Horvath E., Buchfelder M., Fahlbusch R., and Becker W. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report. J Neurosurg 82 (1995) 886-890
89. Colao A., Di Sarno A., Sarnacchiaro F., et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82 (1997) 876-883
90. Tsang R.W., Brierley J.D., Panzarella T., Gospodarowicz M.K., Sutcliffe S.B., and Simpson W.J. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol 41 (1996) 45-53
91. Bevan J.S. Management of pituitary tumours. BMJ 318 (1999) 1226-1227
92. Clayton R.N., and Wass J.A. Pituitary tumours: recommendations for service provision and guidelines for management of patients. Summary of a consensus statement of a working party from the Endocrinology and Diabetes Committee of The Royal College of Physicians and the Society for Endocrinology in conjunction with the Research Unit of the Royal College of Physicians. J R Coll Physicians Lond 31 (1997) 628-636
93. Molitch M., Thorner M., and Wilson C. The case for initial surgical removal of certain prolactinomas. J Clin Endocrinol Metab 82 (1997) 996-1000
94. Horwitz R.I., and Horwitz S.M. Adherence to treatment and health outcomes. Arch Intern Med 153 (1993) 1863-1868
95. Rizzo J.A., and Simons W.R. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 19 (1997) 1446-1457 discussion 1424-1445
96. Wandstrat T.L., and Kaplan B. Pharmacoeconomic impact of factors affecting compliance with antibiotic regimens in the treatment of acute otitis media. Pediatr Infect Dis J 16 (1997) S27-S29
97. Czeizel A., Kiss R., Racz K., Mohori K., and Glaz E. Case-control cytogenetic study in offspring of mothers treated with bromocriptine during early pregnancy. Mutat Res 210 (1989) 23-27
98. Raymond J.P., Goldstein E., Konopka P., Leleu M.F., Merceron R.E., and Loria Y. Follow-up of children born of bromocriptine-treated mothers. Horm Res 22 (1985) 239-246
99. van't Verlaat J.W., and Croughs R.J. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol (Oxford) 34 (1991) 175-178